What do systematic reviews say?

Add‐on felbamate vs placebo

• Felbamate add‐on therapy for drug‐resistant focal epilepsy 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 236 participants
  Very low

Rituximab vs placebo

It is very uncertain whether summary of findings table ‐ Rituximab changes adverse effects compared with placebo (very low certainty).

• Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
  RR 2.46 [0.84, 7.18]
  1 study · 25 participants
  Very low

Intervention not reported

• Amniotic membrane transplantation for acute ocular burns 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 92 participants
  Low

Intervention not reported

• Amniotic membrane transplantation for acute ocular burns 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 36 participants
  Low

Continuous positive airway pressure (CPAP) vs supportive treatment

• Continuous positive airway pressure (CPAP) for acute bronchiolitis in children 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  GRADE not reported

Laser therapy vs no laser therapy

• Laser therapy for retinopathy in sickle cell disease 2022 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 414 participants
  Low

Full opioid agonists vs different full opioid agonists or partial opioid agonists (methadone versus buprenorphine)

Full opioid agonists showed no clear difference in adverse effects compared with different full opioid agonists or partial opioid agonists (methadone… (low certainty).

• Opioid agonist treatment for people who are dependent on pharmaceutical opioids 2022 · Cochrane Headline outcomes only
  RR 0.45 [0.09, 2.41]
  3 studies · 206 participants
  Low

Action observation vs control: effect on upper limb rehabilitation after stroke

• Action observation for upper limb rehabilitation after stroke 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 16 participants
  GRADE not reported

Exercise plus PD&P vs PD&P only

• Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Very low

Exercise vs underwater PEP (uPEP; also known

It is very uncertain whether exercise changes adverse effects compared with underwater PEP (uPEP; also known (very low certainty).

• Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 13 participants
  Very low

Exercise vs ACBT

It is very uncertain whether exercise changes adverse effects compared with ACBT (very low certainty).

• Exercise versus airway clearance techniques for people with cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 18 participants
  Very low

Systemic antibiotics alone vs systematic antibiotics plus antibiotic lock solution

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Catheter guidewire exchange vs catheter removal and replacement

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Systemic antibiotics plus antibiotic lock solutions plus tissue plasminogen activator vs systemic antibiotics plus antibiotic lock solutions plus heparin

The review found no eligible studies for this question.

• Interventions for treating catheter‐related bloodstream infections in people receiving maintenance haemodialysis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pre‐emptive antifungal therapy vs empirical antifungal therapy

• Pre‐emptive antifungal therapy versus empirical antifungal therapy for febrile neutropenia in people with cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1074 participants
  Very low

D‐mannose (2 g) vs nitrofurantoin (50 mg)

It is very uncertain whether D‐mannose (2 g) changes adverse effects compared with nitrofurantoin (50 mg) (very low certainty).

• D‐mannose for preventing and treating urinary tract infections 2022 · Cochrane Headline outcomes only
  RR 0.28 [0.13, 0.57]
  1 study · 206 participants
  Very low

D‐mannose (2 g) vs no treatment

It is very uncertain whether D‐mannose (2 g) changes adverse effects compared with no treatment (very low certainty).

• D‐mannose for preventing and treating urinary tract infections 2022 · Cochrane Headline outcomes only
  RR 16.84 [0.98, 287.92]
  1 study · 205 participants
  Very low

Topical antibiotics vs another topical antibiotic or placebo

• Antibiotic prophylaxis for corneal abrasion 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Summary of findings ‐ initiation of penicillin prophylaxis vs placebo

• Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 457 participants
  Low

Recombinant human growth hormone vs placebo or no intervention

• Recombinant growth hormone therapy for X‐linked hypophosphatemia in children 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 20 participants
  Low